Chiome Bioscience discovers antibody drug candidates for diseases with high unmet medical need, working mainly in basic research, discovery and preclinical development. It out-licenses candidates and related patents to pharmaceutical companies, earning upfront, milestone and royalty payments, and also carries out collaborative research.
Its drug discovery support business serves pharmaceutical and diagnostics companies, universities and research institutes. Services include antibody generation with its ADLib system and B Cell Cloning technology, and expression and purification of antibodies and other proteins. It had 63 employees as of June 30, 2026.
0
open positions at Chiome Bioscience
No live listings from Chiome Bioscience right now — browse all Tokyo software jobs instead.